FLT3 and acute myeloid leukemia: Building upon the efficacy of the HMA + venetoclax regimen in patients with newly diagnosed AML, several studies are now evaluating lower-intensity therapy + venetoclax + FLT3 inhibitor triplets in patients with newly diagnosed FLT3-mutated AML.